Product Description
Mechanisms of Action: BZD Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Bulgaria | Chile | Colombia | France | Jordan | Lebanon | Malta | Morocco | Pakistan | Peru | Russia | South Africa | Tunisia | Ukraine | Venezuela | Vietnam
Approved Indications: None
Company: Biocodex
Company Location: Europe
Company Founding Year: 1953
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bipolar Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2021-006773-38 |
2021-006773-38 | P2 |
Active, not recruiting |
Bipolar Disorder |
2025-02-23 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/28/2023 |
News Article |
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting |
|
03/06/2023 |
News Article |
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates |
|
01/09/2023 |
News Article |
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917 |
|
10/20/2022 |
News Article |
atai Life Sciences Announces R&D Day Agenda |